Table 3.
Multivariable Cox regression analysis of clinical outcome in advanced ovarian cancer patients (FIGO III/IV) with respect to clinical parameters and tumor biological factors.
| Clinical parameters | OS | PFS | ||||
|---|---|---|---|---|---|---|
|
| ||||||
| No.a | HR (95% CI)b | P | No.a | HR (95% CI)b | P | |
|
| ||||||
| Age | 0.148 | 0.860 | ||||
| ≤ 60 years | 37 | 1 | 35 | 1 | ||
| > 60 years | 38 | 1.55 (0.86-2.82) | 34 | 1.06 (0.57-1.94) | ||
|
| ||||||
| Residual tumor mass | 0.001 | 0.034 | ||||
| 0 mm | 36 | 1 | 35 | 1 | ||
| > 0 mm | 39 | 3.56 (1.63-7.78) | 34 | 2.30 (1.06-4.96) | ||
|
| ||||||
| Ascitic fluid volume | 0.941 | 0.382 | ||||
| ≤ 500 ml | 41 | 1 | 39 | 1 | ||
| > 500 ml | 34 | 0.97 (0.48-1.98) | 30 | 1.38 (0.67-2.84) | ||
|
| ||||||
| KLK6 mRNA(med)c | 0.039 | 0.539 | ||||
| low | 40 | 1 | 39 | 1 | ||
| high | 35 | 1.85 (1.03-3.31) | 30 | 1.21 (0.66-2.21) | ||
|
| ||||||
| KLK6 mRNA (61st)d | 0.005 | 0.541 | ||||
| low | 49 | 1 | 48 | 1 | ||
| high | 26 | 2.33 (1.29-4.19) | 21 | 1.21 (0.65-2.27) | ||
|
| ||||||
| KLK8 mRNAc | 0.756 | 0.094 | ||||
| low | 40 | 1 | 37 | 1 | ||
| high | 35 | 0.91 (0.50-1.65) | 32 | 1.66 (0.92-3.02) | ||
|
| ||||||
| KLK6+KLK8 mRNAc | 0.317 | 0.113 | ||||
| low | 28 | 1 | 27 | 1 | ||
| high | 47 | 1.40 (0.73-2.68) | 42 | 1.68 (0.89-3.20) | ||
a
Number of patients
b
HR: hazard ratio (CI: confidence interval) of multivariable Cox regression analysis. Biological markers were separately added to the base model of clinical parameters: age, residual tumor mass, and ascitic fluid volume.
c
Dichotomized into high and low levels by the median.
d
Dichotomized into high and low levels by the 61st percentile.